publication . Article . 2015

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

Tiffany A. Traina; Kathy D. Miller; Denise A. Yardley; Joyce A. O'Shaughnessy; Javier Cortes; Ahmad Awada; Catherine M. Kelly; Maureen E. Trudeau; Peter Schmid; Luca Gianni; ...
  • Published: 20 May 2015 Journal: Journal of Clinical Oncology, volume 33, pages 1,003-1,003 (issn: 0732-183X, eissn: 1527-7755, Copyright policy)
  • Publisher: American Society of Clinical Oncology (ASCO)
1003 Background: The AR may be a therapeutic target for pts with androgen-driven TNBC. ENZA, a potent AR inhibitor, is approved in men with metastatic castration-resistant prostate cancer (mCRPC) and improves median PFS compared to bicalutamide in men with mCRPC (15.7 vs 5.8 mos; HR 0.44; p 0% by IHC; NCT01889238). Pts could be prescreened for AR, and have non-measurable bone disease and unlimited prior regimens; CNS metastases or seizure history were exclusionary. The primary endpoint was clinical benefit (CR, PR or SD) at 16 wks (CBR16) in ‘Evaluable’ pts defined as having both AR IHC ≥10% and a response assessment. CBR24, PFS, response rate, and safety were a...
Persistent Identifiers
Sustainable Development Goals: 10. No inequality6. Clean water
free text keywords: Cancer Research, Oncology, Clinical endpoint, Prostate cancer, medicine.disease, medicine, Phases of clinical research, business.industry, business, Internal medicine, medicine.medical_specialty, Triple-negative breast cancer, Oncology, Gynecology, Gene signature, Androgen receptor, Bicalutamide, medicine.drug, Enzalutamide, chemistry.chemical_compound, chemistry
Download from
Any information missing or wrong?Report an Issue